SIRPα Antibody Combined with Oncolytic Virus OH2 Protects against Tumours by Activating Innate Immunity and Reprogramming the Tumor Immune Microenvironment

Scientists verified the polarization and activation of OH2 in RAW264.7 cells in vitro. Subsequently, they evaluated the antitumour ability of OH2 and anti-SIRPα combined therapy in a tumour-bearing mouse model.